Date
Title
View
14 Feb 20
4basebio AG: 4basebio AG announces results of the public share buyback offerand final purchase price for the share buy back (news with additional features)
View
10 Feb 20
4basebio AG: 4basebio AG decides to increase the public share buyback offer volume from 2,056,452 to 5,230,726 shares (news with additional features)
View
21 Jan 20
4basebio AG: 4basebio AG decides to buy back 2 million treasury shares (news with additional features)
View
21 Jan 20
4basebio AG: Expedeon AG completes change of name to 4basebio AG and of ticker symbol to 4BSB (news with additional features)
View
02 Jan 20
Expedeon AG: Expedeon AG and Abcam plc close EUR 120 million transaction (news with additional features)
View
19 Dec 19
Expedeon AG: Expedeon shareholders approve sale of proteomics & immunotherapy business and name change to 4basebio AG (news with additional features)
View
21 Nov 19
Expedeon AG: Expedeon to Present at the Deutsches Eigenkapitalforum in Frankfurt / Main (news with additional features)
View
20 Nov 19
Expedeon AG: Expedeon AG information on EUR 120 million deal with Abcam on dedicated transaction website (news with additional features)
View
11 Nov 19
Expedeon AG: Expedeon AG signs EUR 120 million deal with Abcam for the sale of its immunology and proteomics business
View
07 Nov 19
Expedeon AG: Expedeon AG reports third quarter 2019 financial results with strongest ever revenues and EBITDA (news with additional features)
View
29 Oct 19
Expedeon AG: Expedeon AG raises adjusted EBITDA guidance for 2019 (news with additional features)
View
04 Oct 19
Expedeon AG: Expedeon AG announces conversion to registered shares (news with additional features)
View